Skip to main content
Log in

Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

An Author Correction to this article was published on 08 July 2020

This article has been updated

Abstract

Survival was examined from a Turkish liver transplant center of patients with HCC, to identify prognostic factors. Data from 215 patients who underwent predominantly live donor liver transplant for HCC at our institute over 12 years were included in the study and prospectively recorded. They were 152 patients within and 63 patients beyond Milan criteria. Patients beyond Milan criteria were divided into two groups according to presence or absence of tumor recurrence. Recurrence-associated factors were analyzed. These factors were then applied to the total cohort for survival analysis. We identified four factors, using multivariate analysis, that were significantly associated with tumor recurrence. These were maximum tumor diameter, degree of tumor differentiation, and serum AFP and GGT levels. A model that included all four of these factors was constructed, the ‘Malatya criteria.’ Using these Malatya criteria, we estimated DFS and cumulative survival, for patients within and beyond these criteria, and found statistically significant differences with improved survival in patients within Malatya criteria of 1, 5, and 10-year overall survival rates of 90.1%, 79.7%, and 72.8% respectively, which compared favorably with other extra-Milan extended criteria. Survival of our patients within the newly defined Malatya criteria compared favorably with other extra-Milan extended criteria and highlight the usefulness of serum AFP and GGT levels in decision-making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The raw data used to support the findings of this study are available from the corresponding author upon request.

Change history

  • 08 July 2020

    The original version of this article unfortunately contained a mistake in the author group section.

Abbreviations

AFP:

Alpha fetoprotein

ALKP:

Alkaline phosphatase

BCLC:

Barcelona Clinic Liver Cancer extended criteria

BMI:

Body mass index

CHILD:

Child-Pugh score

DFS:

Disease-free survival

ETC:

Extended Toronto criteria

GGT:

Gamma glutamyl transferase

GRWR:

Graft to recipient weight ratio

HC:

Hagzhou criteria

HCC:

Hepatocellular cancer

LT:

Liver transplantation

LDLT:

Live donor liver transplantation

MC:

Milan criteria

MELD:

Model for End Stage Liver Disease score

MRI:

Magnetic resonance imaging

MSCT:

Multislice computed tomography

MTD:

Maximal tumor diameter

NLR:

Neutrophil-lymphocyte ratio

OS:

Overall survival

OR:

Odds ratio

PET/CT:

Positron emission tomography/computerized tomography scan

PLR:

Platelet-to-lymphocyte ratio

ROC:

Receiver operating characteristics

TTS:

Total tumor size

UCSF:

University of California, San Francisco criteria

References

  1. World cancer report. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014

  2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  CAS  Google Scholar 

  3. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.

    Article  CAS  Google Scholar 

  4. Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan criteria (Barcelona clinic liver cancer extended criteria). Liver Transplant. 2018;24:369–79.

    Article  Google Scholar 

  5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, de Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, van Hoek B, Majno P, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.

    Article  Google Scholar 

  6. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6):2077–88.

    Article  Google Scholar 

  7. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–32.

    Article  CAS  Google Scholar 

  8. Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S. Living donor liver transplantation for hepatocellular carcinoma. Transplant Proc. 2012;44(6):1713–6.

    Article  CAS  Google Scholar 

  9. Kayaalp C, Ince V, Ersan V, Karakas S, Kahraman AS, Yilmaz S. Liver transplantation for hepatocellular carcinoma at Inonu University. J Gastrointest Cancer. 2017;48(3):268–71.

    Article  Google Scholar 

  10. Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int. 2009;22(9):869–75.

    Article  Google Scholar 

  11. Mazzaferro V, Battiston C, Sposito C. Pro (with caution): extended oncologic indications in liver transplantation. Liver Transpl. 2018;24(1):98–103.

    Article  Google Scholar 

  12. Patel SS, Arrington AK, McKenzie S, et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol. 2012;2012:253517.

    Article  Google Scholar 

  13. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DSK, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246(3):502–9.

    Article  Google Scholar 

  14. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62(1):158–65.

    Article  CAS  Google Scholar 

  15. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008;14(7):935–45.

    Article  Google Scholar 

  16. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13(12):1637–44.

    Article  Google Scholar 

  17. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19(12):1343–53.

    Article  Google Scholar 

  18. Carr BI, Guerra V, Giannini EG, et al. An HCC aggressiveness index and blood GTP, bilirubin and platelet levels. J Integr Oncol. 2016;5:172. https://doi.org/10.4172/2329-6771.1000172.

    Article  Google Scholar 

  19. Carr BI, Guerra V, Giannini EG, et al. A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol. 2016;5(4):178.

    Article  Google Scholar 

  20. Akkiz H, Carr BI, Yalçın KK, et al. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology. 2018;94(2):116–24.

    Article  CAS  Google Scholar 

  21. Wang NY, Zhang D, Zhao W, Fang GX, Shi YL, Duan MH. Clinical applicaton of an enzyme-linked immunosorbent assay detecting hepatoma-spesific gamma-glutamyltransferase. Hepatol Res. 2009;39:979–87.

    Article  CAS  Google Scholar 

  22. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6(3):241–7.

    CAS  PubMed  Google Scholar 

  23. Xia J, Song P, Sun Z, Sawakami T, Jia M, Wang Z. Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma. Drug Discov Ther. 2016;10(4):181–7.

    Article  CAS  Google Scholar 

  24. Lee SD, Kim SH. Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016;5(5):408–14.

    Article  Google Scholar 

  25. Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19(10):1108–18.

    Article  Google Scholar 

  26. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12(8):1260–7.

    Article  Google Scholar 

  27. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–51.

    Article  Google Scholar 

Download references

Acknowledgments

The authors declare that there is no funding used for the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Volkan Ince.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: The original version of this article unfortunately contained a mistake in the author group section. The correct name of the second author is “Sami Akbulut”.

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ince, V., Akbulut, S., Otan, E. et al. Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Canc 51, 998–1005 (2020). https://doi.org/10.1007/s12029-020-00424-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00424-w

Keywords

Navigation